Cover Image
市場調查報告書

CLL Pharma- 產品平台檢討

CLL Pharma - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 310652
出版日期 內容資訊 英文 21 Pages
訂單完成後即時交付
價格
Back to Top
CLL Pharma- 產品平台檢討 CLL Pharma - Product Pipeline Review - 2015
出版日期: 2015年04月15日 內容資訊: 英文 21 Pages
簡介

CLL Pharma Amiodarone是總公司設置於法國的製藥企業,從事學名藥及Galenical製劑的開發。擁有Amiodarone、azithromycin、milnacipran、tramadol等產品,提供注射,藥丸,瓶,崩解劑,膠囊,個別包裝的洗口液,單回使用吸入器用藥粉、口嚼錠等劑型。

本報告提供CLL Pharma的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

CLL Pharma的基本資料

  • CLL Pharma概要
  • 主要資訊
  • 企業資料

CLL Pharma:R&D概要

  • 主要的治療範圍

CLL Pharma:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

CLL Pharma:開發中產品概況

  • 臨床階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式

CLL Pharma:藥物簡介

  • SYN-1002
  • Syn-2001
  • Syn-2004

CLL Pharma:開發平台分析

  • 標的別
  • 各分子類型
  • 各作用機制

CLL Pharma:開發暫停中的計劃

CLL Pharma:總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06987CDB

Summary

Global Markets Direct's, 'CLL Pharma - Product Pipeline Review - 2015', provides an overview of the CLL Pharma's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of CLL Pharma's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of CLL Pharma including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of CLL Pharma's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the CLL Pharma's pipeline products

Reasons to buy

  • Evaluate CLL Pharma's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of CLL Pharma in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the CLL Pharma's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of CLL Pharma and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of CLL Pharma
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of CLL Pharma and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • CLL Pharma Snapshot
    • CLL Pharma Overview
    • Key Information
    • Key Facts
  • CLL Pharma - Research and Development Overview
    • Key Therapeutic Areas
  • CLL Pharma - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • CLL Pharma - Pipeline Products Glance
    • CLL Pharma - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • CLL Pharma - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • CLL Pharma - Drug Profiles
    • SYN-1002
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Syn-2001
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Syn-2004
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • CLL Pharma - Pipeline Analysis
  • CLL Pharma - Pipeline Products by Target
  • CLL Pharma - Pipeline Products by Molecule Type
  • CLL Pharma - Pipeline Products by Mechanism of Action
  • CLL Pharma - Dormant Projects
  • CLL Pharma - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • CLL Pharma, Key Information
  • CLL Pharma, Key Facts
  • CLL Pharma - Pipeline by Indication, 2015
  • CLL Pharma - Pipeline by Stage of Development, 2015
  • CLL Pharma - Monotherapy Products in Pipeline, 2015
  • CLL Pharma - Phase I, 2015
  • CLL Pharma - Preclinical, 2015
  • CLL Pharma - Discovery, 2015
  • CLL Pharma - Pipeline by Target, 2015
  • CLL Pharma - Pipeline by Molecule Type, 2015
  • CLL Pharma - Pipeline Products by Mechanism of Action, 2015
  • CLL Pharma - Dormant Developmental Projects,2015

List of Figures

  • CLL Pharma - Pipeline by Top 10 Indication, 2015
  • CLL Pharma - Pipeline by Stage of Development, 2015
  • CLL Pharma - Monotherapy Products in Pipeline, 2015
  • CLL Pharma - Pipeline by Top 10 Target, 2015
  • CLL Pharma - Pipeline by Top 10 Molecule Type, 2015
  • CLL Pharma - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top